HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPRGet Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 492.59% from the stock’s previous close.

ESPR has been the subject of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Monday. Bank of America downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $9.33.

View Our Latest Analysis on ESPR

Esperion Therapeutics Stock Up 3.1 %

Shares of NASDAQ ESPR opened at $2.70 on Monday. The firm has a market cap of $499.64 million, a price-to-earnings ratio of -1.27 and a beta of 0.82. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.34. The business’s 50 day moving average is $2.37 and its two-hundred day moving average is $1.79.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same period in the prior year, the company posted ($0.76) EPS. Analysts anticipate that Esperion Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ESPR. Wasatch Advisors LP boosted its stake in shares of Esperion Therapeutics by 95.0% in the 1st quarter. Wasatch Advisors LP now owns 13,354,186 shares of the biopharmaceutical company’s stock valued at $21,233,000 after purchasing an additional 6,505,808 shares during the last quarter. Wasatch Advisors Inc. raised its position in shares of Esperion Therapeutics by 27.6% in the 1st quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company’s stock valued at $37,804,000 after acquiring an additional 1,761,117 shares during the period. Vanguard Group Inc. raised its position in shares of Esperion Therapeutics by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 5,137,750 shares of the biopharmaceutical company’s stock valued at $15,362,000 after acquiring an additional 396,388 shares during the period. Balyasny Asset Management L.P. raised its position in shares of Esperion Therapeutics by 39.1% in the 1st quarter. Balyasny Asset Management L.P. now owns 4,771,360 shares of the biopharmaceutical company’s stock valued at $7,586,000 after acquiring an additional 1,342,223 shares during the period. Finally, Armistice Capital LLC acquired a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $5,850,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Further Reading

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.